Skip to main content
Fig. 3 | BMC Veterinary Research

Fig. 3

From: Investigating the role of signal transducer and activator of transcription 3 in feline injection site sarcoma

Fig. 3

The effect of 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12) on the cell viability of the primary cells derived from feline injection site sarcomas (FISSs) and feline normal soft tissues evaluated at 72 h of treatment. The FISS-10 and FISS-14 primary cells (A) and the normal feline soft tissue cells (B) were treated with different concentrations of LLL12 in triplicate. The inhibitory effects of LLL12 on cell proliferation were evaluated at 24, 48 and 72 h of LLL12 treatment by the Alamar Blue assay. DMSO was used for dissolving the LLL12 and was used as a vehicle control. Data are present as mean ± SD. *Statistically significant from the controls (P < 0.05)

Back to article page